Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1551-1552, 2003; 10.1373/49.9.1551
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lennard, L.
Right arrow Articles by Oellerich, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lennard, L.
Right arrow Articles by Oellerich, M.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2003;49:1551-1552.)
© 2003 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Commentary on: Differences in Nucleotide Hydrolysis Contribute to the Differences between Erythrocyte 6-Thioguanine Nucleotide Concentrations Determined by Two Widely Used Methods

Lynne Lennard1

1 University of Sheffield, Division of Clinical Sciences (South) Academic Unit of Molecular and Clinical Pharmacology, Royal Hallamshire Hospital, (Floor L), Glossop Rd., Sheffield S10 2JF, United Kingdom

The first 20% of the full text of this article appears below.


To the Editor:

In their article, Shipkova et al. (1) present evidence to indicate that the concentration of erythrocyte thioguanine nucleotides (TGNs) measured by the method of Lennard (2) differ considerably from those measured by the method of Dervieux and Boulieu (3). The assay method studied by Shipkova et al. was superseded over a decade ago for studies of thiopurine metabolism (4). However, Shipkova et al. have made a valid observation. Both assays (2)(3) are based on the same general principle, hydrolysis of the thionucleotide back to the parent thiopurine before measurement of the liberated thiopurine by HPLC. Shipkova et al. (1) attribute the differences in the TGN concentrations measured, in part, to the hydrolysis protocols of the two methods. However, despite the differences recorded in the TGN concentrations measured, there was an excellent and highly significant correlation between the two methods.

For the optimization of thiopurine therapy, Shipkova et al. (1) make a plea for method-independent therapeutic ranges and the standardization of analytical procedures. However, the former is difficult when the main obstacle is the lack of commercially available, quality-assured thiopurine standards. To investigate thionucleotide hydrolysis, . . . [Full Text of this Article]

Maria ShipkovaR1,a, Victor William ArmstrongR2, Eberhard WielandR1 and Michael OellerichR2

R1 Department of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, D-70174 Stuttgart, Germany

R2 Department of Clinical Chemistry, Georg-August-University Göttingen, D-37075 Göttingen, Germany

aAddress correspondence to this author at: Department of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Kriegsbergstrasse 60, D-70174 Stuttgart, Germany. Fax 49-711-2784809; e-mail maria.shipkova@nexgo.de






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.